167. Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies

BACKGROUND: Microbiota-based treatments have shown promise to reduce recurrence, morbidity, and mortality for recurrent Clostridioides difficile infections (rCDI), but consistent and reliable clinical efficacy data are needed to support regulatory approvals that broaden patient access. Here we provi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bancke, Lindy, Su, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Oral Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644833/
http://dx.doi.org/10.1093/ofid/ofab466.167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644833/
http://dx.doi.org/10.1093/ofid/ofab466.167

Ejemplares similares